BEPOTASTINE BESILATE solution

Bepotastine Besilate by

Drug Labeling and Warnings

Bepotastine Besilate by is a Prescription medication manufactured, distributed, or labeled by Somerset Therapeutics, LLC, Somerset Therapeutics Private Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Bepotastine besilate ophthalmic solution 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis.

  • 2 DOSAGE AND ADMINISTRATION

    Instill one drop of bepotastine besilate ophthalmic solution into the affected eye(s) twice a day.

    Remove contact lenses prior to instillation of bepotastine besilate ophthalmic solution.

  • 3 DOSAGE FORMS AND STRENGTHS

    Ophthalmic solution containing bepotastine besilate 15 mg/mL (1.5%).

  • 4 CONTRAINDICATIONS

    Bepotastine besilate ophthalmic solution is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients [see Adverse Reactions (6.2)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Contamination of Tip and Solution

    To minimize contaminating the dropper tip and solution, advise the patient not to touch the eyelids or surrounding areas with the dropper tip of the bottle and to keep the bottle tightly closed when not in use.

    5.2 Contact Lens Wear

    Bepotastine besilate ophthalmic solution should not be used to treat contact lens-related irritation.

    Bepotastine besilate ophthalmic solution should not be instilled while wearing contact lenses. Patient should remove contact lenses prior to instillation of bepotastine besilate ophthalmic solution, because benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bepotastine besilate ophthalmic solution.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

    The most common reported adverse reaction occurring in approximately 25% of subjects was a mild taste following instillation. Other adverse reactions occurring in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.

    6.2 Post-Marketing Experience

    Hypersensitivity reactions have been reported rarely during the post-marketing use of bepotastine besilate ophthalmic solution. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The hypersensitivity reactions may include itching, body rash, and swelling of lips, tongue and/or throat.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no available human data for the use of bepotastine besilate ophthalmic solution during pregnancy to inform any drug-associated risks.

    Oral administration of bepotastine besilate to pregnant rats or rabbits during organogenesis or during the pre/postnatal period did not produce adverse embryofetal or offspring effects at clinically relevant systemic exposures. Maternal toxicity was observed in the rabbits at the lowest dose administered, 20 mg/kg/day (215 times the maximum recommended human ophthalmic dose, RHOD, on a mg/m2 basis) [see Data].

    The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.

    Data

    Animal Data

    In embryofetal development studies, oral administration of bepotastine besilate to pregnant rabbits throughout organogenesis did not produce teratogenic effects at maternal doses up to 500 mg/kg/day (approximately 5.400 times the maximum RHOD, on a mg/m2 basis). A maternal no observed adverse effect level (NOAEL) was not identified in this study due to spontaneous abortion observed at the lowest dose tested, 20 mg/kg/day (approximately 215 times higher than the maximum RHOD, on a mg/m2 basis). Oral administration of bepotastine besilate to pregnant rats throughout organogenesis produced skeletal anomalies at 1,000 mg/kg/day (5,400 times higher than the maximum RHOD, on a mg/m2 basis), a dose that also produced maternal toxicity and lethality. No teratogenic effects were observed in rats at maternal doses up to 200 mg/kg/day (corresponding to an estimated blood plasma concentration 3,300 times higher than that anticipated in humans at the maximum RHOD). A maternal NOAEL was observed at 10 mg/kg/day (54 times higher than the maximum RHOD, on a mg/m2 basis). Following a single 3 mg/kg oral dose in rats (16 times higher than the maximum RHOD, on a mg/m2 basis), the concentration of radio-labeled bepotastine besilate was similar in fetal liver and maternal blood plasma. The concentration in other fetal tissues was one-third to one-tenth the concentration in maternal blood plasma.

    In a pre/postnatal development study, oral administration of bepotastine besilate to rats during the perinatal and lactation periods produced an increase in stillbirths and decreased growth and development in offspring at a maternal dose of 1,000 mg/kg/day (5400 times higher than the maximum RHOD, on a mg/m2 basis). There were no observed adverse effects on offspring of rats treated with 100 mg/kg/day (540 times higher than the maximum RHOD, on a mg/m2 basis). Effects on parturition and maternal lethality were observed at 100 mg/kg/day and 1,000 mg/kg/day, respectively. A maternal NOAEL was observed at 10 mg/kg/day (54 times higher than the maximum RHOD, on a mg/m2 basis).

    8.2 Lactation

    Risk Summary

    There are no data on the presence of bepotastine besilate ophthalmic solution in human milk, the effects on the breastfed infant or the effects on milk production.

    The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for bepotastine besilate ophthalmic solution, and any potential adverse effects on the breastfed infant from bepotastine besilate ophthalmic solution.

    Animal Data

    Following a single 3 mg/kg oral dose (16 times the maximum RHOD, on a mg/m2 basis) of radio-labeled bepotastine besilate to nursing rats 11 days after delivery, the maximum concentration of radioactivity in milk was 0.40 mcg-eq/mL 1 hour after administration; at 48 hours after administration, the radioactivity concentration was below detection limits. The milk radioactivity concentration was higher than the maternal blood plasma radioactivity concentration at each time of measurement. It is not known whether bepotastine besilate would be present in maternal milk following topical ocular administration.

    8.4 Pediatric Use

    Safety and efficacy of bepotastine besilate ophthalmic solution 1.5% have not been established in pediatric patients under 2 years of age. Efficacy in pediatric patients under 10 years of age was extrapolated from clinical trials conducted in pediatric patients greater than 10 years of age and from adults.

    8.5 Geriatric Use

    No overall differences in safety or effectiveness have been observed between elderly and younger patients.

  • 11 DESCRIPTION

    Bepotastine besilate ophthalmic solution 1.5% is a sterile, topically administered drug for ophthalmic use. Each mL of bepotastine besilate ophthalmic solution contains 15 mg bepotastine besilate.

    Bepotastine besilate is designated chemically as (+) -4-[[(S)-p-chloro-alpha -2  pyridylbenzyl]oxy]-1-piperidine butyric acid monobenzenesulfonate. The chemical structure for bepotastine besilate is:

    Image

    Bepotastine besilate is a white or pale yellowish crystalline powder. The molecular weight of bepotastine besilate is 547.06 daltons. Bepotastine besilate ophthalmic solution is supplied as a sterile, aqueous 1.5% solution, with a pH of 6.8.

    The osmolality of bepotastine besilate ophthalmic solution 1.5% is approximately 290 mOsm/kg.

    Each mL of bepotastine besilate ophthalmic solution 1.5% contains:

    • Active: bepotastine besilate 15 mg (equivalent to 10.7 mg bepotastine)
    • Preservative: benzalkonium chloride 0.005%
    • Inactives: monobasic sodium phosphate dihydrate, sodium chloride, sodium hydroxide to adjust pH, and water for injection, USP.
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Bepotastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.

    12.3 Pharmacokinetics

    Absorption: The extent of systemic exposure to bepotastine following topical ophthalmic administration of bepotastine besilate 1% and 1.5% ophthalmic solutions was evaluated in 12 healthy adults. Following one drop of 1% or 1.5% bepotastine besilate ophthalmic solution to both eyes four times daily (QID) for 7 days, bepotastine plasma concentrations peaked at approximately 1 to 2 hours post-instillation. Maximum plasma concentrations for the 1% and 1.5% strengths were 5.1 ± 2.5 ng/mL and 7.3 ± 1.9 ng/mL, respectively. Plasma concentrations at 24 hours post-instillation were below the quantifiable limit (2 ng/mL) in 11/12 subjects in the two dose groups.

    Distribution: The extent of protein binding of bepotastine is approximately 55% and independent of bepotastine concentration.

    Metabolism: In vitro metabolism studies with human liver microsomes demonstrated that bepotastine is minimally metabolized by CYP450 isozymes.

    In vitro studies demonstrated that bepotastine besilate does not inhibit the metabolism of various cytochrome P450 substrates via inhibition of CYP3A4, CYP2C9, and CYP2C19. The effect of bepotastine besilate on the metabolism of substrates of CYP1A2, CYP2C8 and CYP2D6 was not studied. Bepotastine besilate has a low potential for drug interaction via inhibition of CYP3A4, CYP2C9, and CYP2C19.

    Excretion: The main route of elimination of bepotastine besilate is urinary excretion (with approximately 75-90% excreted unchanged in urine).

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    Long-term dietary studies in mice and rats were conducted to evaluate the carcinogenic potential of bepotastine besilate. Bepotastine besilate did not significantly induce neoplasms in mice receiving a nominal dose of up to 200 mg/kg/day for 21 months, or in rats receiving a nominal dose of up to 97 mg/kg/day for 24 months. These dose levels correspond to systemic exposures approximately 350 and 200 times higher than that achieved at the RHOD, respectively.

    The no observable adverse effect level for bepotastine besilate based on nominal dose levels in carcinogenicity tests were 18.7 to 19.9 mg/kg/day in mice and 9.6 to 9.8 mg/kg/day in rats (corresponding to systemic exposures approximately 60 and 20 times higher than that anticipated in humans at RHOD, respectively).

    Mutagenesis

    There was no evidence of genotoxicity in the Ames test (mutagenicity), in CHO cells (chromosome aberration), in mouse hepatocytes (unscheduled DNA synthesis), or in the mouse micronucleus test.

    Impairment of Fertility

    Oral administration of bepotastine to male and female rats at doses up to 1,000 mg/kg/day (5,400 times higher than the maximum RHOD, on a mg/m2 basis) resulted in reduction in fertility index and surviving fetuses. Oral administration of bepotastine besilate produced no observed adverse effects on fertility or reproduction in rats at oral doses up to 200 mg/kg/day (corresponding to an estimated blood plasma concentration 3,300 times higher than that anticipated in humans at the RHOD).

  • 14 CLINICAL STUDIES

    Clinical efficacy was evaluated in two conjunctival allergen challenge (CAC) studies (237 patients). Bepotastine besilate ophthalmic solution 1.5% was more effective than its vehicle for relieving ocular itching induced by an ocular allergen challenge, both at a CAC 15 minutes post-dosing and a CAC 8 hours post-dosing of bepotastine besilate ophthalmic solution.

    The safety of bepotastine besilate ophthalmic solution was evaluated in a randomized clinical study of 861 subjects over a period of 6 weeks.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Bepotastine besilate ophthalmic solution 1.5% is supplied in a white LDPE bottle with a white LDPE nozzle and a white HDPE cap in the following size:

    5 mL – NDC 70069-711-01

    10 mL – NDC 70069-712-01

    STORAGE

    Store at 15°C to 25°C (59°F to 77°F).

  • 17 PATIENT COUNSELING INFORMATION

    • Sterility of Dropper Tip

    Advise patients not to touch the dropper tip to any surface, as this may contaminate the solution and to keep the bottle tightly closed when not in use.

    • Concomitant Use of Contact Lenses

    Advise patients not to wear a contact lens if their eye is red and that bepotastine besilate ophthalmic solution should not be used to treat contact lens-related irritation. Patients should also be advised to remove contact lenses prior to instillation of bepotastine besilate ophthalmic solution, which may be reinserted after 10 minutes following administration.

  • SPL UNCLASSIFIED SECTION

    Manufactured for:

    Somerset Therapeutics, LLC

    Somerset, NJ 08873

    Made in India

    Code No.: KR/DRUGS/KTK/28/289/97

    1201019

    ST-BPO/P/01

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Container Label

    NDC: 70069-711-01

    BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5%

    Sterile

    FOR TOPICAL OPHTHALMIC USE

    Rx only

    5 mL

    Image

    Carton Label

    NDC: 70069-711-01

    BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5%

    Sterile

    FOR TOPICAL OPHTHALMIC USE

    Rx only

    5 mL

    Image

    Container Label

    NDC: 70069-712-01

    BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5%

    Sterile

    FOR TOPICAL OPHTHALMIC USE

    Rx only

    10 mL

    Image

    Carton Label

    NDC: 70069-712-01

    BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5%

    Sterile

    FOR TOPICAL OPHTHALMIC USE

    Rx only

    10 mL

    Image
  • INGREDIENTS AND APPEARANCE
    BEPOTASTINE BESILATE 
    bepotastine besilate solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 70069-711
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BEPOTASTINE BESILATE (UNII: 6W18MO1QR3) (BEPOTASTINE - UNII:HYD2U48IAS) BEPOTASTINE BESILATE15 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)  
    SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 70069-711-011 in 1 CARTON10/10/2024
    15 mL in 1 BOTTLE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21777010/10/2024
    BEPOTASTINE BESILATE 
    bepotastine besilate solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 70069-712
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BEPOTASTINE BESILATE (UNII: 6W18MO1QR3) (BEPOTASTINE - UNII:HYD2U48IAS) BEPOTASTINE BESILATE15 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)  
    SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 70069-712-011 in 1 CARTON10/10/2024
    110 mL in 1 BOTTLE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21777010/10/2024
    Labeler - Somerset Therapeutics, LLC (079947873)
    Registrant - Somerset Therapeutics, LLC (079947873)
    Establishment
    NameAddressID/FEIBusiness Operations
    Somerset Therapeutics Private Limited677236695ANALYSIS(70069-711, 70069-712) , LABEL(70069-711, 70069-712) , PACK(70069-711, 70069-712) , MANUFACTURE(70069-711, 70069-712)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.